BBSRC-STFC DeepTech Catalyst Bio: Historical 2026 Opportunity

BBSRC-STFC DeepTech Catalyst Bio: Historical 2026 Opportunity

Status and historical reference

The 2026 BBSRC-STFC DeepTech Catalyst Bio (DTC Bio) opportunity is closed. UK Research and Innovation (UKRI) lists the call as closed and gives 14 September 2026 as its final application deadline. The official opportunity page does not announce a later round. This page therefore records the terms and process of the closed 2026 call for reference; it is not an invitation to apply. Applicants should rely on a newly published UKRI opportunity page for any future round rather than assume that the dates or application route described here will repeat.

The funding opportunity was run by UKRI through the Biotechnology and Biological Sciences Research Council (BBSRC) and the Science and Technology Facilities Council (STFC). It was described as a business incubator programme for early-stage biotechnology start-ups seeking to develop commercial potential. The call combined direct R&D support with an innovation voucher and access to business, technical and intellectual property support. UKRI also described networking opportunities and access to a number of its campuses.

DTC Bio had previously been called the BBSRC-STFC Biotechnology Business Incubation Centre (Bio BIC). That former name helps explain references to the programme in older records, but the 2026 opportunity page used the DTC Bio name.

Funding and programme support

The maximum award listed by UKRI was £50,000. The programme description separately specified £50,000 of R&D funding and a £10,000 innovation voucher for R&D activity. The voucher was an additional part of the stated support package, not a replacement for the R&D funding. The official page did not publish a minimum award amount in the opportunity summary, so this historical listing makes no claim about a minimum or about how an individual company’s final package would be structured.

The programme also included technical, commercial, business and intellectual property support. UKRI described opportunities to network and receive introductions to investors, customers and sector stakeholders, alongside access to a number of UKRI campuses. The named locations were STFC Sci-Tech Daresbury, the BBSRC campuses of Rothamsted Enterprises and AberInnovation, and specialist support available from The Pirbright Institute. The page described these as programme support and access; it did not promise a particular amount of campus time, a guaranteed investor introduction, or a specific service to every company.

For a company considering a future opportunity with a similar structure, these components suggest that its work plan would need to connect technical activity with commercial development. That is a preparation observation, not a new eligibility test. The closed call’s published eligibility requirements and application sequence are set out below as UKRI stated them.

Who was eligible for the 2026 call

Applicants had to be UK-registered companies under five years old and majority-owned by founders and employees. In addition, the company had to have received one or more qualifying forms of previous support. UKRI listed three routes:

• A BBSRC or other UKRI grant that supported the research underpinning the company’s product or service.
• An Innovate UK or other UKRI commercialisation grant to take forward a bioscience innovation addressing a market opportunity.
• Support from a UKRI-supported accelerator or pre-incubation programme.

The underpinning technology had to be within BBSRC remit. UKRI said it should be biological in nature, interact with a biological entity, involve a biological process, or address a biological challenge. The research had to take forward a bioscience innovation in response to a clear market opportunity. A company needed to demonstrate that it was beyond the concept stage of product development or market penetration, or both.

These criteria describe both the company and the lineage of the proposed work. A qualifying organisation alone was not enough: its proposed technology had to build on previous support and fit the biological scope. Likewise, evidence of prior support did not remove the requirement to show progress beyond concept and a defined market opportunity. Companies with uncertainty about whether their technology fitted the scope were strongly advised by UKRI to contact the programme team.

The call excluded applications based on medical or clinical devices and therapeutics being developed solely for a specific end-point clinical utility, including diagnostics. This wording is narrower than a general exclusion of every health-related or diagnostic-adjacent innovation. The relevant question was whether the application was based solely on the specified clinical endpoint utility and whether its underlying technology met the call’s BBSRC and bioscience requirements.

The official page stated that a single company would apply through the process. It did not describe a consortium award structure in the material reviewed. Companies preparing supporting collaborations would have needed to ensure that the applicant company, rather than an unclear group of partners, was the applicant represented in the EOI and any invited full application.

Application process used in the closed round

The process began with an expression of interest (EOI), submitted using the DTC Bio EOI application form linked from the UKRI page. Each company could submit only one EOI. UKRI strongly encouraged companies to submit as early as possible and set 16 August 2026 as the latest EOI date. Submissions were reviewed on an ongoing basis, with EOIs considered in three phases: 26 June 2026, 17 July 2026, and 16 August 2026 for the final tranche.

Approval of the EOI was a prerequisite for the next stage. Successful applicants were invited to submit a full application and provided with an application template. The full application deadline was 14 September 2026. The opportunity page also said applicants could request feedback on draft applications before that final deadline and encouraged early submission so there would be time to incorporate feedback.

This was a competitive selection process. The staged design meant that completing an EOI did not itself constitute a full application or guarantee an award. A company needed to first pass the EOI stage, then prepare and submit the invited full application by the deadline. The official page did not publish a direct route for companies to bypass the EOI and send a full application at the outset.

Successful applicants were invited to present at an in-person evaluation board taking place from 20 to 22 October. That interview stage followed the full application deadline. The source does not state that every EOI submitter would attend, or that attendance itself guaranteed selection. The date range is included here because it formed part of the published 2026 process.

Materials and preparation relevant to the published criteria

UKRI’s opportunity page linked the EOI form and said successful EOI applicants would receive the full application template. It did not provide a definitive checklist of supporting documents in the guidance reviewed. The following preparation points translate the stated eligibility and assessment sequence into practical records a company could assemble; they should not be mistaken for additional official submission requirements.

A company would have benefited from keeping a clear record of its UK registration date and ownership, so it could substantiate the under-five-year and founder-and-employee-majority criteria. It would also have needed a traceable record of the qualifying previous support: the funder or programme, the support received, and its connection to the current product or service. The connection matters because UKRI required the technology to build on prior BBSRC, UKRI or UKRI-supported accelerator or pre-incubation support.

For the technical case, useful evidence could include development results that show progress beyond concept. The exact evidence depends on the technology. A company might explain what has been built, tested or validated and how that work advances product development or market penetration. It should connect the chosen evidence to the biological nature of the technology and explain how the work falls within BBSRC remit. The official page does not mandate a particular technology-readiness-level label or a specific prototype, assay, or dataset.

The market case should make the opportunity intelligible: who has the problem, how the bioscience innovation addresses it, and what commercial progress the company aims to make. This follows UKRI’s stated interest in taking a bioscience innovation forward to address a clear market opportunity. A plan for the support package could then link R&D activities and voucher-funded activity to credible outcomes, while showing where the programme’s technical, commercial, business or IP support would be useful. This is sensible preparation, not a published budget template or a promise that every cost would be eligible.

Finally, an applicant should have followed the live instructions attached to the official form and any full application template supplied after EOI approval. Because this round is closed, those forms should not be treated as open application links or as authoritative instructions for a future round. A new call may revise its criteria, required materials, support package or deadlines.

Published dates and programme timeline

UKRI gave the opening date as 11 May 2026 at 9:00am UK time. The opportunity page also listed a webinar for potential applicants on 18 June 2026 at 2:00pm. EOI review tranches were dated 26 June 2026, 17 July 2026 and 16 August 2026. The final EOI cut-off was 16 August 2026 at 11:59pm, and the final full application deadline was 14 September 2026 at 11:59pm. Successful applicants were invited to an in-person evaluation board from 20 to 22 October.

These dates belong to the closed 2026 call. The 14 September 2026 deadline remains in the metadata because it is the real closing date of this historical opportunity, while historicalReference = true identifies the page as an archive entry. A future DTC Bio call would need its own official notice before its date or status could be added here.

Contact and official source

The UKRI page gave the DTC Bio team contact email as [email protected] and advised applicants who were unsure about programme scope to contact the team. The official opportunity page is the source for the closed call’s award amount, eligibility, programme description, application process and dates:

• Official 2026 opportunity: https://www.ukri.org/opportunity/bbsrc-stfc-deeptech-catalyst-bio-2026/
• Programme contact listed by UKRI: [email protected]

UKRI’s page currently marks the opportunity closed. No subsequent DTC Bio round is announced there, so prospective applicants should check UKRI’s official opportunity listings and obtain a new published call before acting on any of the historical terms above.